Detalhe da pesquisa
1.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med
; 386(12): 1143-1154, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320644
2.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
3.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
4.
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Cancer
; 129(12): 1919-1929, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970876
5.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825569
6.
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Invest New Drugs
; 41(3): 421-430, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37074571
7.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol
; 172: 82-91, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001446
8.
Novel Estrogen Receptor-Targeted Agents for Breast Cancer.
Curr Treat Options Oncol
; 24(7): 821-844, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129836
9.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Lancet Oncol
; 23(12): 1558-1570, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400106
10.
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.
Oncologist
; 27(9): 722-731, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35704278
11.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Breast Cancer Res Treat
; 195(1): 55-64, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829935
12.
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Breast Cancer Res Treat
; 195(2): 127-139, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545724
13.
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
BMC Cancer
; 22(1): 502, 2022 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35524219
14.
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol
; 166(2): 219-229, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690498
15.
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Gynecol Oncol
; 158(3): 640-645, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513564
16.
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol
; 158(3): 631-639, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534811
17.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Int J Cancer
; 145(7): 1798-1808, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680712
18.
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Gynecol Oncol
; 154(2): 314-322, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31204078
19.
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 19(7): 880-888, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29804905
20.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Breast Cancer Res Treat
; 167(3): 671-686, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063313